Bristol-Myers Squibb (NYSE:BMY) Stock Position Trimmed by Webster Bank N. A.

Webster Bank N. A. trimmed its holdings in Bristol-Myers Squibb (NYSE:BMY) by 18.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,509 shares of the biopharmaceutical company’s stock after selling 6,314 shares during the quarter. Webster Bank N. A.’s holdings in Bristol-Myers Squibb were worth $1,759,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Security Asset Management boosted its holdings in shares of Bristol-Myers Squibb by 20.3% in the first quarter. Security Asset Management now owns 9,230 shares of the biopharmaceutical company’s stock valued at $640,000 after acquiring an additional 1,558 shares in the last quarter. Richard P Slaughter Associates Inc increased its position in shares of Bristol-Myers Squibb by 3.5% during the 2nd quarter. Richard P Slaughter Associates Inc now owns 22,040 shares of the biopharmaceutical company’s stock valued at $1,409,000 after purchasing an additional 750 shares during the period. Talbot Financial LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth $4,482,000. Ethic Inc. lifted its holdings in shares of Bristol-Myers Squibb by 26.4% in the first quarter. Ethic Inc. now owns 121,524 shares of the biopharmaceutical company’s stock valued at $8,423,000 after buying an additional 25,385 shares during the period. Finally, Atlas Wealth LLC bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $276,000. 74.98% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Up 0.2 %

BMY stock traded up $0.10 during midday trading on Tuesday, reaching $58.68. The company had a trading volume of 4,660,209 shares, compared to its average volume of 8,976,633. The company has a 50 day moving average of $61.62 and a two-hundred day moving average of $65.11. The company has a current ratio of 1.39, a quick ratio of 1.28 and a debt-to-equity ratio of 1.08. Bristol-Myers Squibb has a 1 year low of $58.33 and a 1 year high of $81.43. The company has a market capitalization of $122.59 billion, a P/E ratio of 15.58, a PEG ratio of 1.57 and a beta of 0.42.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.24). Bristol-Myers Squibb had a net margin of 17.62% and a return on equity of 50.51%. The firm had revenue of $11.23 billion for the quarter, compared to analyst estimates of $11.81 billion. During the same period in the previous year, the business posted $1.93 EPS. Bristol-Myers Squibb’s revenue for the quarter was down 5.6% on a year-over-year basis. On average, equities research analysts expect that Bristol-Myers Squibb will post 7.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. HSBC began coverage on shares of Bristol-Myers Squibb in a research report on Friday, July 14th. They set a “reduce” rating and a $56.00 price objective for the company. Atlantic Securities decreased their price target on shares of Bristol-Myers Squibb from $90.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, July 28th. Daiwa Capital Markets assumed coverage on Bristol-Myers Squibb in a research report on Wednesday, June 28th. They set an “outperform” rating and a $70.00 price objective for the company. Barclays decreased their target price on Bristol-Myers Squibb from $64.00 to $62.00 and set an “equal weight” rating on the stock in a report on Friday, July 28th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $70.67.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, EVP Ann Powell sold 17,986 shares of the stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the transaction, the executive vice president now owns 27,868 shares of the company’s stock, valued at approximately $1,706,915. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Robert M. Plenge sold 732 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $61.14, for a total transaction of $44,754.48. Following the completion of the transaction, the executive vice president now owns 6,584 shares of the company’s stock, valued at approximately $402,545.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ann Powell sold 17,986 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total value of $1,101,642.50. Following the completion of the sale, the executive vice president now directly owns 27,868 shares in the company, valued at approximately $1,706,915. The disclosure for this sale can be found here. Corporate insiders own 0.08% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.